M032
AXP000086.1 · Oncolytic virus
- Platform
- HSV-1 (strain F, gamma34.5-deleted)
- Originator
- University of Alabama at Birmingham
- Sponsor
- University of Alabama at Birmingham
Names
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- F
- Replication
- conditionally replicating
- Modifications
- both copies of gamma34.5 deleted; human IL-12 expression cassette inserted
- Transgenes
- IL12A, IL12B
- Route
- intratumoral, intracerebral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07076498 | Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation | Recruiting | Phase 1 | 2026-04-23 | 2029-12-31 | 20 | Glioma |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | Recruiting | Phase 1/2 | 2022-02-25 | 2027-03-01 | 28 | Anaplastic Astrocytoma; Glioblastoma Multiforme; Gliosarcoma |
| NCT02062827 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | Completed | Phase 1 | 2013-11-25 | 2022-09 | 29 | Anaplastic Astrocytoma or Gliosarcoma; Progressive Glioblastoma Multiforme; Recurrent Glioblastoma Multiforme |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 27314913 | Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. | Human gene therapy. Clinical development | 2016 | name in title: M032 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33524948 | Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. | Neurosurgical focus | 2021 | name in title: M032 |
| PMID 33005623 | The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. | Frontiers in surgery | 2020 | name in title: M032 |
| PMID 24649838 | Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. | Human gene therapy. Clinical development | 2014 | name in title: M032 |
Unconfirmed matches (5)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: M032 |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: M032 |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: M032 |
| PMID 35342877 | Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus. | Journal of translational genetics and genomics | 2021 | name in abstract: M032 |
| PMID 30224769 | Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. | Scientific reports | 2018 | name in abstract: M032 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA217179 | A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. | UNIVERSITY OF ALABAMA AT BIRMINGHAM | MARKERT, JAMES M | 2017–2019 | name in title: M032 |
Unconfirmed matches (4)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R33NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | LSU HEALTH SCIENCES CENTER | KAUR, BALVEEN | 2026–2026 | name in abstract: M032 |
| R61NS128191 | Development of murine glioblastoma model for oncolytic HSV therapy | AUGUSTA UNIVERSITY | KAUR, BALVEEN | 2024–2025 | name in abstract: M032 |
| U01CA224151 | Canine Immuno Neurotherapeutics | UNIVERSITY OF ALABAMA AT BIRMINGHAM | CHAMBERS, M R | 2017–2021 | name in abstract: M032 |
| P01CA071933 | Engineered HSV For Treatment of Malignant Glioma | UNIVERSITY OF ALABAMA AT BIRMINGHAM | WHITLEY, RICHARD J. | 2009–2013 | name in abstract: M032 |
Notes
gamma34.5-deleted oHSV carrying human IL-12 (the murine counterpart is M002). Phase 1 in recurrent glioma (NCT02062827); a further phase 1 in diffuse midline glioma opened in 2025 (NCT07076498). No NCIt concept found for M032.
How to cite
M032 (AXP000086.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000086.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.